Abnormal movement in US stocks | Eli Lilly and Company (LLY.US) rises by nearly 2%, up 16% in the month

According to the Ufin APP, on Wednesday, Eli Lilly (LLY.US) rose nearly 2%, hitting a new all-time high, with a cumulative increase of 16% for the month. In terms of news, Lilly announced an agreement with the US government to lower the price of GLP-1 drugs to $245 per month in exchange for federal Medicare coverage, opening up a new market of approximately 30 million people, with an annual sales potential of $27 billion. Citibank has significantly raised Lilly's target price from $1250 to $1500, enhancing market recognition of the company's value.